News

M&S Technologies has released a new software for its Smart System 2020 and PC-Plus visual acuity, contrast sensitivity and video media systems.

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease.

Neurotech Pharmaceuticals has begun enrolment for two Phase II/III clinical trials of NT-501; it's lead Encapsulated Cell Technology (ECT) product for the treatment for retinitis pigmentosa (RP).

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.

CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD).

The FDA has approved InSite Vision's New Drug Application (NDA) for AzaSite (azithromycin 1%) for the treatment of bacterial conjunctivitis.

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations.

Therapeutic interventions, in particular for neovascular age-related macular degeneration (AMD) offer a better degree of value than any other treatment right across the field of healthcare.

Cup-to-disc ratios and visual field evaluations using telemedicine-friendly devices are the most useful tools for glaucoma screening.

Carl Zeiss Meditec has united its sales and marketing activities in Germany.

Optical coherence tomography (OCT) is a useful tool for determining when re-treatments with ranibizumab are required in patients with neovascular age-related macular degeneration (AMD).

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD).

The sutureless method of transplantation of fibrin glue-coated, freeze-dried amniotic membrane (FCFD-AM) is both safe and straightforward.

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions.

A Phase I/II clinical trial has been initiated to evaluate an innovative gene therapy in patients with progressive deterioration in vision caused by an abnormality in the RPE65 gene.

AMO has launched an online series featuring US TV star Kristin Cavallari.

Patients who are repeatedly treated with bevacizumab (Avastin) for choroidal neovascularization (CNV) experience visual improvements similar to patients who received their first treatment with the drug.

Long waiting times have become a progressively important issue, particularly in countries with publicly funded systems.

Ellex Medical Lasers has received FDA 510(k) approval to market the Ellex 30XL laser slit lamp.

The AcrySof angle-supported phakic refractive IOL (Alcon) continues to offer patients with high myopia stable and accurate refractive results with excellent visual acuity (VA), according to physicians speaking at the XXIV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in London last September.

The introduction of anti-VEGF therapy has revolutionized the treatment of neovascular age-related macular degeneration (AMD); the main cause of blindness in the industrialized world. Large numbers of previously untreatable patients will now be eligible for treatment which, in itself, represents an overwhelming challenge to healthcare providers. Discussion and careful planning is needed to ensure that the manpower and funds are in place to deal with this new era in ophthalmic care.

It is an accepted fact that people in the UK have one of the poorest diets in Europe; with the consumption of poor-quality, low-priced foods, along with lack of exercise fuelling the rise in obesity amongst many other diseases.

A review of the various studies that have investigated the best way to treat macular oedema secondary to CRVO.

Pilot study, which examines the benefits of combining photodynamic therapy (PDT) with bevacizumab (Avastin) in AMD patients, yields promising results.

Correction of very high myopia, i.e. above –9.00 D, remains a controversial topic and new designs of phakic IOLs have spurred great interest in the past five years. Presently, long-term results are becoming available and some interesting conclusions can be drawn, explained Matteo Piovella, MD, who reported his four-year results with one of these lenses at the XXIV Congress of the European Society of Cataract and Refractive Surgeons in London.

Are clear corneal incisions safe? Veteran practitioner says 'yes'

Zeiss: all under one umbrella

Highlights from an expert roundtable meeting on coaxial microincision cataract surgery.